2007 Fiscal Year Final Research Report Summary
Impact of Mesenchymal stem cell transplantation in mouse GVHD model
| Project/Area Number |
18591195
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
SUZUKI Nobuhiro Sapporo Medical University, School of Medicine, Associate professor (50216420)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HATAKEYAMA Naoki Sapporo Medical University, School of Medicine, Assistant professor (40404660)
YAMAMOTO Masaki Sapporo Medical University, School of Medicine, Assistant professor (80404664)
HORI Tsukasa Sapporo Medical University, School of Medicine, Assistant professor (20398324)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Keywords | Transplantation / mesenchymal stem cell / Graft versus host disease / mouse model |
|---|
| Research Abstract |
Using mouse model for graft versus host disease (GVHD), we studied effects of mesenchymal stem cell (MSC) on severity, prognosis of GVHD. 2×107 bone marrow cells isolated form C57BL/6 mice were transplanted to lethally irradiated BALB/c mice. An apparent GVHD was observed 7 days after marrow transplantation (BMT), which continued to day 28, the last day for observations. To develop various severity in GVHD, we added various number of spleen cells obtained from C57BL/6 mice. 1×10 spleen cells plus 1×107 marrow cells developed lethal GVHD. More than 50% of recipients dyed before day14. Using this very severe GVHD model, we exploited whether transplantation of MSC decrease GVHD severity in this particular model. MSC were prepared using Mruine Mesencult culture system. Cell surface markers of our MSC were CD45^-, CD11b-, Sca+, CD44+. These MSC could differentiate to osteoblasts and lipocytes under appropriate conditions. Using various number of MSC, GVHD model was challenged for effects of MSC transplantation. MSCs were transplanted on either the day of BMT or one day after BMT. These mice were compared to those of non MSC recipient mice which were received only bone marrow cells. Clinical symptom, body weight, survival date and pathological findings were studied at day7, 14,21 and 28 after BMT, though none of these findings were changed in both MSC recipients and BMT only recipients. We are planning to do BMT with immunosuppressive reagent plus MSC on different severity of GVHD model as a next trial
|
Research Products
(2 results)
